Selection and genetic characterization of streptococcus pneumoniae mutants resistant to the Des-F(6) quinolone BMS-284756

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 10, 2001, Pages 2865-2870

  Hartman Neumann, S ^a   Denbleyker, K ^a   Pelosi, L A ^a   Lawrence, L E ^a   Barrett, J F ^a   Dougherty, T J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GARENOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIUM COLONY; BACTERIUM MUTANT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA STRAND; ENZYME INHIBITION; GENE GYRA; GENE GYRB; GENE MUTATION; GENE PARC; GENE PARE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; INDOLES; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION; QUINOLONES; SELECTION (GENETICS); STREPTOCOCCUS PNEUMONIAE;

EID: 0034805830     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.10.2865-2870.2001     Document Type: Article

References (41)

1. Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase
2. Prevalence of putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
3. Crystal structure of the breakage-reunion domain of DNA gyrase
4. DNA gyrase and topoisomerase on the bacterial chromosome: Quinolone-induced DNA cleavage
5. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
6. DNA gyrase, topoisomerase IV, and the 4-quinolones
7. Mechanism of fluoroquinolone action
8. DNA topoisomerase IV as a quinolone target
9. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
10. Antibacterial spectrum of a novel des-fluoro(6)quinolone, BMS-284756
11. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae
12. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and toposiomerase IV, an in vivo target preference for gyrase and enhanced stabilization of cleavable complexes in vitro
13. Bacterial topoisomerases, anti-topoisomerases and anti-topoisomerase resistance
14. Mechanisms of fluoroquinolone resistance
15. Mode of action of fluoroquinolones
16. Mechanisms of action of antimicrobials: Focus on fluoroquinolones
17. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
18. New topoisomerase essential for chromosome segregation in E. coli
19. Gatifloxacin activity against quinolone-resistant gyrase: Enhancement of bacteriostatic and bacteriocidal activities by the C-8-O-methoxy group
20. Cloning and simplified purification of Escherichia coli DNA gyrase A and B proteins
21. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones
22. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of quinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
23. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
24. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in fluoroquinolone resistance
25. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
26. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
27. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification and differential inhibition by fluoroquinolones
28. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
29. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones
30. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
31. Mechanisms of fluoroquinolone resistance: An update 1994-1998
32. DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolini acid
33. Gyrase and topo IV modulate chromosome domain size in vivo
34. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin
35. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone
36. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
37. Minimizing quinolone resistance: Are the new agents more or less likely to cause resistance?
38. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
39. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex
40. Transcription generates positively and negatively supercoiled domains in the template
41. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli